论文部分内容阅读
Cervical cancer is pathology of high incidence world-wide.The World Organization of the Health (WHO) has reported historically the appearance of 500000 new cases of this disease at global level, every year.In addition to the surgery, the radio and chemotherapy constitute the main treatment for this type of tumor at present.Immunotherapeutic strategies and combinations of different drug regimens have been used to treat cervical cancer, although the potential toxic effect and biodistribution remain to be unsolved problems.Protein Kinase 2 (CK2) has been involved on the malignant transformation in cancer and plays an important role on the adaptive mechanism of tumor cells to avoid apoptosis.The inhibition of this enzyme using antisense gene therapy or small molecules induces apoptosis on tumor cells.Different to the approaches above mentioned, the Center for Genetic Engineering and Biotechnology (Cuba) and Biorec settled down (The Netherlands) have developed a brand new synthetic peptide (CIGB-300) which targets the substrate acidic phosphorylation domain for CK2.CIGB-300 induces apoptosis in tumor cells and regression of solid tumors implanted in mice.Therefore, this peptide has perspectives as a candidate for cancer targeted therapy.